NICE, NHS England and NHS Improvement have taken advice from clinical experts to review the potential impact of COVID-19 on the delivery of the Managed Access Agreement (MAA) for Translarna, a treatment for people with Duchenne muscular dystrophy.
The statement sets out considerations for patients (and/or their carers) who are already receiving treatment and those patients (and/or their carers) who have not yet started treatment.
NICE commented that:
The statement aims to try and ensure consistency in approaches across managed access treatment centres and that all patients receive equivalent services across the country.
The statement is general and some hospitals may have to take additional decisions around how they prioritise resources to tackle COVID-19.
If you have questions about your individual circumstances at your usual treatment centre you should contact the team who manage your treatment.